Notable Quotes
"This outcome speaks to the fundamental role that Genevant's foundational LNP technology played in enabling the world's response to the COVID-19 pandemic. As we continue to pursue our ongoing litigation against Pfizer/BioNTech, whose Comirnaty sales represent ~2/3 of global COVID vaccine sales, this resolution with Moderna reduces uncertainty, validates our IP estate and provides near term significant cash inflow." — Statement on March 3, 2026